Syral
6
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Effect of scFOS on Increase in Stool Frequency in Constipated People
Role: lead
Effects of scFOS on Stool Frequency in People With Functionnal Constipation
Role: lead
Glycaemic and Insulinaemic Responses After Consumption of FOS.
Role: collaborator
Glycaemic and Insulinaemic Responses After Consumption of FOS.
Role: collaborator
Digestive Tolerance of Maltitol and FOS
Role: lead
Effects of follow-on Formula Enriched on Short-chain Fructooligosaccharides (scFOS) on Immune Response in Healthy Infants
Role: lead
All 6 trials loaded